Metrics as of 10/13/2026, 06:38 PM (Berlin time), refresh in progress.
NewAmsterdam Pharma Company Stock
NewAmsterdam Pharma Company N.V.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Netherlands
- CEO
- Michael Harvey Davidson Facp.
- Employees
- 100
- Market cap
- $2.4 B
- IPO
- 09/02/2021
NewAmsterdam Pharma Company N.V. is a biopharmaceutical company operating in the Healthcare sector and Biotechnology industry, headquartered in Naarden, the Netherlands. The late-stage company focuses on developing therapies designed to enhance patient care for populations suffering from cardiometabolic disease. A…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
NewAmsterdam Pharma Company stock: price history
1D
-5.0%
1W
-9.3%
1M
-11.4%
6M
-41.4%
YTD
-42.4%
1Y
-45.7%
2Y
+11.0%
5Y
+105.2%
10Y
–
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~3% weaker price swings than usual
Ask the agents about NewAmsterdam Pharma Company
Analyst assessment of NewAmsterdam Pharma Company
PRICE TARGET LOW
US$45.00
CONSENSUS
US$51.33
MEDIAN
US$51.00
PRICE TARGET HIGH
US$58.00
0
STRONG BUY
9
BUY
1
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 05/10/2026
NewAmsterdam Pharma Company stock metrics
P/E
-9.26
P/B
3.94
EV/EBITDA
-7.6
RETURN ON EQUITY
-10.2%
NET MARGIN
-1,732.9%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
68.5%
FLOAT SHARES
80,068,134
AVG. DAILY VOLUME (30D)
1,687,799
Insider transactions (SEC)
Kastelein Johannes Jacob Pieter
Kastelein Johannes Jacob Pieter
Davidson Michael H.
Smither John W
Gunning Robert William
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -5.0%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about NewAmsterdam Pharma Company stock
What does NewAmsterdam Pharma Company do?
NewAmsterdam Pharma Company N.V. is a company in the Healthcare sector, Biotechnology industry, headquartered in Netherlands.
The CEO is Michael Harvey Davidson Facp., the company employs around 100 people.
The IPO was on 09/02/2021; the stock trades on NASDAQ under the ticker NAMS.
What do analysts say about NewAmsterdam Pharma Company stock?
10 analysts rate the stock, the consensus is Buy (as of 05/10/2026).
The average price target is US$51.33, ranging from US$45.00 to US$58.00, with a median of US$51.00.
This is an external assessment, not a statement by Market Jury.
When does NewAmsterdam Pharma Company report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly -3% stronger than usual.
Does NewAmsterdam Pharma Company pay a dividend?
No, NewAmsterdam Pharma Company currently does not pay a dividend.
Which stocks are comparable to NewAmsterdam Pharma Company?
Comparable stocks include argenx, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get NewAmsterdam Pharma Company stock analyzed?
Clicking "Analyze stock" lets five strategies assess NewAmsterdam Pharma Company against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.